

Raptor Pharmaceutical Corp
Form 8-K
March 15, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 11, 2016

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

000-25571
(Commission

File Number)
7 Hamilton Landing, Suite 100

86-0883978
(IRS Employer

Identification Number)

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Novato, California 94949

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (415) 408-6200

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

The Board of Directors of Raptor Pharmaceutical Corp. (the Company), a Delaware corporation has established Thursday June 23, 2016 as the date of the Company's Annual Meeting of Stockholders (the 2016 Annual Meeting). Stockholders of record at the close of business on April 25, 2016 will be entitled to notice of and to vote upon the matters to be considered at the 2016 Annual Meeting which will be held at the Company's headquarters at 7 Hamilton Landing, Suite 100; Novato, California 94949.

Stockholders of the Company who wish to have a proposal considered for inclusion in the Company's proxy materials for the 2016 Annual Meeting pursuant to Rule 14a-8 under the Exchange Act, must ensure that such proposal is received by the Company's Secretary at the Company's headquarters, on or before the close of business on March 25, 2016, which the Company has determined to be a reasonable time before it expects to begin to print and mail its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible for inclusion in our proxy materials for the 2016 Annual Meeting.

In accordance with the Company's bylaws, stockholders desiring to nominate a director or bring any other business before the stockholders at the 2016 Annual Meeting must notify the Company's corporate secretary in writing no later than the close of business on or before March 25, 2016, the 10th day following public disclosure of the date of the annual meeting. Any notices must be received by the Company at 7 Hamilton Landing, Suite 100; Novato, California 94949, Attn: Corporate Secretary, on or before March 25, 2016 and must set forth the information specified in and comply with all other requirements of the Company's bylaws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 15, 2016

RAPTOR PHARMACEUTICAL CORP.

By: /s/ Michael P. Smith

Name: Michael P. Smith

Title: Chief Financial Officer